Integrative -omics and HLA-ligandomics analysis to identify novel drug targets for ccRCC immunotherapy

BACKGROUND: Clear cell renal cell carcinoma (ccRCC) is the dominant subtype of renal cancer. With currently available therapies, cure of advanced and metastatic ccRCC is achieved only in rare cases. Here, we developed a workflow integrating different -omics technologies to identify ccRCC-specific HL...

Descripción completa

Detalles Bibliográficos
Autores principales: Reustle, Anna, Di Marco, Moreno, Meyerhoff, Carolin, Nelde, Annika, Walz, Juliane S., Winter, Stefan, Kandabarau, Siahei, Büttner, Florian, Haag, Mathias, Backert, Linus, Kowalewski, Daniel J., Rausch, Steffen, Hennenlotter, Jörg, Stühler, Viktoria, Scharpf, Marcus, Fend, Falko, Stenzl, Arnulf, Rammensee, Hans-Georg, Bedke, Jens, Stevanović, Stefan, Schwab, Matthias, Schaeffeler, Elke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7106651/
https://www.ncbi.nlm.nih.gov/pubmed/32228647
http://dx.doi.org/10.1186/s13073-020-00731-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7106651/
https://www.ncbi.nlm.nih.gov/pubmed/32228647
http://dx.doi.org/10.1186/s13073-020-00731-8

Ejemplares similares